作者
Avraham Unterman,Tomokazu Sumida,Nima Nouri,Xiting Yan,Amy Zhao,Victor Gasque,Jonas C. Schupp,Hiromitsu Asashima,Yunqing Liu,Carlos Cosme,Wenxuan Deng,Ming Chen,Micha Sam Brickman Raredon,Kenneth B. Hoehn,Guilin Wang,Zuoheng Wang,Giuseppe DeIuliis,Neal G. Ravindra,Ningshan Li,Christopher Castaldi,Patrick Wong,John Fournier,Santos Bermejo,Lokesh Sharma,Arnau Casanovas‐Massana,Chantal B.F. Vogels,Anne L. Wyllie,Nathan D. Grubaugh,Anthony Melillo,Hailong Meng,Yan Stein,Maksym Minasyan,Subhasis Mohanty,William Ruff,Inessa Cohen,Khadir Raddassi,Allison Nelson,Denise Shepard,Michael Rainone,Xiaohua Peng,Laura E. Niklason,Albert I. Ko,Ruth R. Montgomery,Shelli Farhadian,Akiko Iwasaki,Albert C. Shaw,David van Dijk,Hongyu Zhao,Steven H. Kleinstein,David A. Hafler,Naftali Kaminski,Charles S. Dela Cruz
摘要
Abstract Dysregulated immune responses against the SARS-CoV-2 virus are instrumental in severe COVID-19. However, the immune signatures associated with immunopathology are poorly understood. Here we use multi-omics single-cell analysis to probe the dynamic immune responses in hospitalized patients with stable or progressive course of COVID-19, explore V(D)J repertoires, and assess the cellular effects of tocilizumab. Coordinated profiling of gene expression and cell lineage protein markers shows that S100A hi /HLA-DR lo classical monocytes and activated LAG-3 hi T cells are hallmarks of progressive disease and highlights the abnormal MHC-II/LAG-3 interaction on myeloid and T cells, respectively. We also find skewed T cell receptor repertories in expanded effector CD8 + clones, unmutated IGHG + B cell clones, and mutated B cell clones with stable somatic hypermutation frequency over time. In conclusion, our in-depth immune profiling reveals dyssynchrony of the innate and adaptive immune interaction in progressive COVID-19.